An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 207981
Company: TAIHO ONCOLOGY

Summary Review

Products on NDA 207981

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
LONSURF	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 6.14MG BASE;15MG	TABLET;ORAL	Prescription	AB	Yes	No
LONSURF	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 8.19MG BASE;20MG	TABLET;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 207981

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
09/22/2015	ORIG-1	Approval	Type 1 - New Molecular Entity and Type 4 - New Combination	STANDARD	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207981Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
08/02/2023	SUPPL-12	Efficacy-New Indication	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207981s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/207981Orig1s012ltr.pdf
01/01/2020	SUPPL-9	Labeling-Package Insert	Label (PDF) Letter (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207981s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/207981Orig1s009ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/207981Orig1s009.pdf
02/22/2019	SUPPL-8	Efficacy-New Indication	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/207981Orig1s008ltr.pdf
06/29/2017	SUPPL-6	Labeling-Patient Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207981s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207981Orig1s006ltr.pdf
03/30/2017	SUPPL-4	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207981s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207981Orig1s004ltr.pdf
04/05/2016	SUPPL-3	Manufacturing (CMC)		Label is not available on this site.
11/20/2015	SUPPL-2	Manufacturing (CMC)		Label is not available on this site.
11/13/2015	SUPPL-1	Manufacturing (CMC)		Label is not available on this site.

Labels for NDA 207981

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
08/02/2023	SUPPL-12	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207981s012lbl.pdf
01/01/2020	SUPPL-9	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207981s009lbl.pdf
02/22/2019	SUPPL-8	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf
06/29/2017	SUPPL-6	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207981s006lbl.pdf
03/30/2017	SUPPL-4	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207981s004lbl.pdf
09/22/2015	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf

Therapeutic Equivalents for NDA 207981

LONSURF

TABLET;ORAL; EQ 6.14MG BASE;15MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
LONSURF	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 6.14MG BASE;15MG	TABLET;ORAL	Prescription	Yes	AB	207981	TAIHO ONCOLOGY
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 6.14MG BASE;15MG	TABLET;ORAL	Prescription	No	AB	214024	MSN
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 6.14MG BASE;15MG	TABLET;ORAL	Prescription	No	AB	214008	NATCO

TABLET;ORAL; EQ 8.19MG BASE;20MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
LONSURF	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 8.19MG BASE;20MG	TABLET;ORAL	Prescription	Yes	AB	207981	TAIHO ONCOLOGY
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 8.19MG BASE;20MG	TABLET;ORAL	Prescription	No	AB	214024	MSN
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE	TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE	EQ 8.19MG BASE;20MG	TABLET;ORAL	Prescription	No	AB	214008	NATCO

Top